Skip to main content
PRFX logo
PRFX
(NASDAQ)
PRF Technologies Ltd.
$1.15-- (--)
Loading... - Market loading

PRF Technologies (PRFX) Company Profile

Complete business overview, executive team, trading details, and corporate information.

PRF Technologies Ltd.
PRFXNasdaq Stock MarketHealthcareDrug Manufacturers - Specialty & Generic

About PRF Technologies

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Phone972 3 7177050
Address
65 Yigal Alon St. Tel Aviv-Yafo, 6744316 Israel

Corporate Identifiers

CIK0001801834
CUSIPM77798201
ISINIL0011651580
SIC2834

Leadership Team & Key Executives

Efraim Cohen-Arazi
Interim Chief Executive Officer and Director
Dr. Ehud Geller Ph.D.
Executive Chairman
Eyal Broder
Chief Financial Officer
Dr. Sigal Aviel eMBA, Ph.D.
Chief Operating Officer
Dr. Stephen A. Cooper D.M.D Ph.D.
Executive Vice President of Development
Rita Keynan M.Sc.
Vice President of Pharmaceutical Operations